Crocs' stock drops sharply after its Q4 earnings forecast falls short of consensus estimates
By Steve Gelsi
Crocs Inc.'s stock was down about 9% Thursday after the footwear maker issued fourth-quarter earnings projections that fell short of current analyst estimates, despite its third-quarter results beating expectations.
The company signaled more challenges around its HeyDude brand with its latest 2023 revenue projection of 4% to 6% growth, down from its estimate for 14% to 18% growth over the summer.
Crocs (CROX) said its third-quarter net income rose to $177.03 million, or $2.87 a share, from $169.35 million, or $2.72 a share in the year-ago quarter.
Third-quarter adjusted profit at the Broomfield, Colo.-based company totaled $3.25 a share, well ahead of the FactSet consensus estimate of $3.10 a share.
Revenue rose 6.2% to $1.05 billion, ahead of the estimate of $1.03 billion.
Looking ahead, Crocs said it expects fourth-quarter profit of $2.05 to $2.35 a share, short of the FactSet consensus estimate of $2.78 a share.
The company said adjusted its full-year outlook reflects its shift in strategy around its HeyDude, a footwear brand it acquired in 2022.
"We took decisive action around HeyDude to accelerate our marketplace management strategy to ensure long-term brand health," Crocs Chief Executive Andrew Rees said.
Reflecting on the third quarter, Rees said the company saw "healthy full-price selling and industry-leading operating margins."
Also read: Crocs' stock tumbles 15% after earnings show weakness at high-flying HeyDude brand
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-02-23 1243ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks